Cat. #161202
MCF10A-ERRB2m-13 cell line
Cat. #: 161202
Sub-type: Continuous
Availability: 8-10 weeks
Organism: Human
Tissue: Mammarygland epithelium
Model: Mutant
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Medical-Industrial Translational Research Center
Institute: Fukushima Medical University
Primary Citation: Irie et al. Mol Cancer Ther. 2019 Apr, 18(4):733-742. PMID: 30787176
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: MCF10A-ERRB2m-13 cell line
- Alternate name: 06M15027
- Cancers detailed: Non-tumorigenic
- Research fields: Cancer;Cell biology
- Tool sub type: Continuous
- Parental cell: MCF10A, a non-tumorigenic cell line from human mammarygland epithelium
- Clone: ERBB2_type-15
- Organism: Human
- Tissue: Mammarygland epithelium
- Morphology: Epithelial
- Growth properties: Adherent
- Model: Mutant
- Model description: Type-15; Type mutation: P780_Y781insGSP; CDS mutation: c.2339_2340insGGGCTCCCC; AA mutation: p.P780_Y781insGSP; COSMIC Mutation ID: COSM12555
- Description: Non-tumorigenic immortalized breast epithelial cell stably overexpressing mutant cancer-related gene, ERBB2 (erb-B2 Receptor Tyrosine Kinase 2). ERBB2 is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors.
- Application: Functional analysis of mutated genes, Drug screening
- Biosafety level: 1
Target Details
- Target: Erb-b2 receptor tyrosine kinase 2 [ERBB2]
- Target background: Gene ID: 2064; References: DNA (mRNA): NM_004448.3; Protein: NP_004439.2
Applications
- Application: Functional analysis of mutated genes, Drug screening
Handling
- Format: Frozen
- Growth medium: DMEM/Ham's F-12 supplemented with 5% heat-inactivated horse serum, 10 Â?g/ml insulin (human, recombinant), 5 Â?M forskolin, 0.5 Â?g/ml hydrocortisone, 20 ng/ml EGF (human, recombinant), 100 U/ml penicillin, and 100 Â?g/ml streptomycin
- Temperature: 37° C
- Atmosphere: Humidified incubator with 5%Â CO2
- Shipping conditions: Dry ice
- Storage medium: CELLBANKER 2 (Zenogen pharma)
- Storage conditions: Liquid Nitrogen
- Initial handling information: Thaw the vial at 37 °C in a water bath?then seed cells into a T75 flask. Culture in a humidified Incubator at 37 ? with 5% CO2 in air. Culture medium should be changed every 2 to 3 days.
- Cultured in antibiotics: 100 U/ml Penicillin, and 100 Â?g/ml Streptomycin
- Mycoplasma free: Yes
- Characterisation tests: Comprehensive gene expression analysis; Identification of cell proliferation and cellular form; Drug sensitivity tests
References
- Irie et al. Mol Cancer Ther. 2019 Apr, 18(4):733-742. PMID: 30787176